Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 9/20 | 0.53 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD1 | P21728 | 2/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | DRD5 | P21918 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21645004 | 1.00 | FFAR1 (0.53) | FFAR1DRD2DRD1DRD4DRD5 | |
| SCHEMBL21644846 | 0.90 | FFAR1 (0.49) | FFAR1DRD2DRD1DRD4DRD5 | |
| SCHEMBL21644842 | 0.90 | FFAR1 (0.49) | FFAR1DRD2DRD1DRD4DRD5 | |
| SCHEMBL21644844 | 0.90 | FFAR1 (0.49) | FFAR1DRD2DRD1DRD4DRD5 | |
| SCHEMBL29715919 | 0.89 | FFAR1 (0.44) | FFAR1DRD2DRD1DRD4DRD5 | |
| SCHEMBL20103584 | 0.86 | FFAR1 (0.66) | FFAR1 | |
| SCHEMBL21644949 | 0.81 | FFAR1 (0.52) | FFAR1 | |
| SCHEMBL21644948 | 0.81 | FFAR1 (0.52) | FFAR1 | |
| SCHEMBL29454631 | 0.81 | FFAR1 (0.58) | FFAR1 | |
| SCHEMBL21644929 | 0.80 | FFAR1 (0.48) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-27 | — | — | US | disclosed |
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR65, GPR55 | FFAR1 16/4885DRD2 1097/4885DRD1 1694/4885 |
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | GPR119, GPR65, GPR55 | FFAR1 16/4885DRD2 1097/4885DRD1 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.